Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 577

1.

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.

Scott AW, Bressler SB.

Curr Opin Ophthalmol. 2013 May;24(3):190-6. doi: 10.1097/ICU.0b013e32835fefee. Review.

PMID:
23492430
2.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups.

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
3.

Preferred therapies for neovascular age-related macular degeneration.

Lally DR, Gerstenblith AT, Regillo CD.

Curr Opin Ophthalmol. 2012 May;23(3):182-8. doi: 10.1097/ICU.0b013e328352411c. Review.

PMID:
22450218
4.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
5.

Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.

Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, Hubbard GB 3rd.

Am J Ophthalmol. 2013 Jul;156(1):23-28.e2. doi: 10.1016/j.ajo.2013.02.009. Epub 2013 May 8.

6.

Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.

Peden MC, Suñer IJ, Hammer ME, Grizzard WS.

Ophthalmology. 2015 Apr;122(4):803-8. doi: 10.1016/j.ophtha.2014.11.018. Epub 2015 Jan 14.

PMID:
25596618
7.

Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.

Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.

Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.

PMID:
22414958
8.

Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.

Freund KB, Hoang QV, Saroj N, Thompson D.

Ophthalmology. 2015 Sep;122(9):1802-10. doi: 10.1016/j.ophtha.2015.04.018. Epub 2015 May 27.

PMID:
26025097
9.

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.

Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, Mahajan VB.

Am J Ophthalmol. 2013 Jul;156(1):15-22.e1. doi: 10.1016/j.ajo.2013.02.017. Epub 2013 May 22.

PMID:
23706500
10.

Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.

Messenger WB, Campbell JP, Faridi A, Shippey L, Bailey ST, Lauer AK, Flaxel CJ, Hwang TS.

Br J Ophthalmol. 2014 Sep;98(9):1205-7. doi: 10.1136/bjophthalmol-2013-304829. Epub 2014 May 2.

PMID:
24795334
11.

Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.

Johnson D, Sharma S.

Curr Opin Ophthalmol. 2013 May;24(3):205-12. doi: 10.1097/ICU.0b013e32835f8ec0. Review.

PMID:
23518613
12.

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS.

Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.

PMID:
24084500
13.

Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration.

Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB.

Retina. 2013 Sep;33(8):1605-12. doi: 10.1097/IAE.0b013e31828e8551.

PMID:
23549101
14.

Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.

Yuzawa M, Fujita K, Wittrup-Jensen KU, Norenberg C, Zeitz O, Adachi K, Wang EC, Heier J, Kaiser P, Chong V, Korobelnik JF.

Ophthalmology. 2015 Mar;122(3):571-8. doi: 10.1016/j.ophtha.2014.09.024. Epub 2014 Nov 6.

PMID:
25439429
15.

Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.

Zehetner C, Kralinger MT, Modi YS, Waltl I, Ulmer H, Kirchmair R, Bechrakis NE, Kieselbach GF.

Acta Ophthalmol. 2015 Mar;93(2):e154-9. doi: 10.1111/aos.12604. Epub 2014 Dec 8.

16.

Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.

Veloso CE, Kanadani TM, Pereira FB, Nehemy MB.

Ophthalmology. 2015 Aug;122(8):1569-72. doi: 10.1016/j.ophtha.2015.04.028. Epub 2015 May 30.

PMID:
26038338
17.

Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.

Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB.

J Glaucoma. 2012 Apr-May;21(4):241-7. doi: 10.1097/IJG.0b013e31820d7d19.

PMID:
21423038
18.

Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).

Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, Lopez PF.

Retina. 2012 Mar;32(3):434-57. doi: 10.1097/IAE.0B013E31822C290F.

PMID:
22374154
19.

Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.

Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Eliott D, Vavvas DG, Miller JW, Kim IK.

Am J Ophthalmol. 2013 Jul;156(1):29-35.e2. doi: 10.1016/j.ajo.2013.03.030. Epub 2013 May 10.

PMID:
23668679
20.

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, Baird PN, Guymer RH.

Ophthalmology. 2013 Jan;120(1):115-21. doi: 10.1016/j.ophtha.2012.10.006. Epub 2012 Nov 11.

PMID:
23149126

Supplemental Content

Support Center